Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00650442

Enrollment

Registered

2008-04-01

Start date

2003-01-31

Completion date

2003-02-28

Last updated

2008-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The primary objective of this study was to compare the adhesive quality of the current Mylan estradiol placebo transdermal system, with that of an alternate second generation Mylan estradiol placebo transdermal system following a single system application. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system.

Interventions

DRUGEstradiol Transdermal System Placebo - Alternate Adhesive

single application

DRUGEstradiol Transdermal System Placebo - Current Adhesive

single application

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

40 Years to 66 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age: 40-66 years. 2. Sex: Females only. 3. Weight: At least 52 kg (115 lbs) and within 20% of Ideal Body Weight (IBW), as referenced by the Table of Desirable Weights of Adults from Metropolitan Life Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY STUDY PROTOCOLS). 4. All subjects should be judged normal and healthy during a prestudy medical evaluation (physical examination, laboratory evaluation and 12-lead ECG) performed within 14 days of the initial patch application.

Exclusion criteria

1. Institutionalized subjects will not be used. 2. Any prior history of skin diseases (eczema, psoriasis, atopic dermatitis). 3. Damaged skin in or around test sites that include sunburn, uneven skin tones, tattoos, scars or other disfigurations of the test site. 4. Abnormal and clinically significant laboratory test results: 1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY STUDY PROTOCOLS). 2. Abnormal and clinically relevant ECG tracing. 5. Subjects who have received an investigational drug within 30 days prior to the initial patch application and/or participated in any transdermal system test for irritation or sensitization within the last 4 weeks. 6. Allergy or hypersensitivity to any tapes or adhesives (ex. band-aids, medical tape).

Design outcomes

Primary

Measure	Time frame
Transdermal Adhesion	within 30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026